

### (19) World Intellectual Property Organization International Bureau



# 

### (43) International Publication Date 14 July 2005 (14.07.2005)

## **PCT**

# (10) International Publication Number WO 2005/063232 A1

(71) Applicant (for all designated States except US): MD

BIOALPHA CO., LTD. [KR/KR]; #1713, Honor's Ville, 1380-1, Dunsan-dong, Seo-gu, Daejeon 302-120 (KR).

Inventors/Applicants (for US only): KWAK, Taehwan [KR/KR]; 103-503, Seogeunaemaeul SK Apt.,

Seocheon-ri, Giheung-eup, Yongin-si, Gyeonggi-do

449-906 (KR). PARK, Myunggyu [KR/KR]; 107-302, Seogeunaemaeul SK Apt., Seocheon-ri, Giheung-eup,

2-cha Bldg., 642-16, Yoksam 1-dong, Kangnam-gu, Seoul

(74) Agent: SOHN, Chang Kyu; 1403, Seongji Heights

(51)	International Patent Classification7:	A61K 31/343,	10-2004-0036197	21 May 2004 (21.05.2004)	KR
	35/78, A61P 3/04		10-2004-0050200	30 June 2004 (30.06.2004)	KR

(72) Inventors; and

135-910 (KR).

(21) International Application Number:

PCT/KR2004/003546

(22) International Filing Date:

30 December 2004 (30.12.2004)

(25) Filing Language: Korean

**English** (26) Publication Language:

(30) Priority Data: 10-2003-0099658

30 December 2003 (30.12.2003)

30 December 2003 (30.12.2003)

10-2003-0099556 10-2003-0099557

30 December 2003 (30.12.2003) KR

30 December 2003 (30.12.2003) KR

**KR** 10-2003-0099657 KR


> (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

Yongin-si, Gyeonggi-do 449-906 (KR).

10-2004-0036195 21 May 2004 (21.05.2004) KR

[Continued on next page]

(54) Title: OBESITY AND METABOLIC SYNDROME TREATMENT WITH TANSHINONE DERIVATIVES WHICH **INCREASE METABOLIC ACTIVITY** 



(57) Abstract: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.





#### 

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.